
Image Credit: Scientific Frontline
Scientific Frontline: "At a Glance" Summary
- Main Discovery: Inhibition of the epigenetic co-activators p300/CBP prevents alveolar type 2 (AT2) cells from becoming trapped in a pathogenic "alveolar transitional cell state" (ATCS), thereby blocking the progression of idiopathic pulmonary fibrosis (IPF).
- Methodology: Researchers utilized a phenotypic drug screen of 264 compounds on human iPS cell-derived models and validated efficacy using a bleomycin-induced mouse lung injury model and a telomere-driven senescence model.
- Key Data: The p300/CBP inhibitor CBP30 significantly decreased fibrotic gene expression and myofibroblast activation, while single-cell profiling identified CD54 (ICAM1) as a distinct surface marker for isolating pathogenic ATCS cells.
- Significance: This study demonstrates that the accumulation of ATCS is a reversible, epigenetically driven process central to fibrosis, identifying a novel therapeutic target for a disease characterized by irreversible tissue scarring.
- Future Application: Development of targeted p300/CBP inhibitors as a new class of antifibrotic drugs for treating idiopathic pulmonary fibrosis and potentially other interstitial lung diseases.
- Branch of Science: Regenerative Medicine / Epigenetics.
- Additional Detail: Transcriptomic analysis confirmed that the iPS cell-derived ATCS (iATCs) generated in the study closely match the pathological cell states found in the lungs of human IPF patients.



_MoreDetail-v3_x2_730x524.jpg)




